Abstract: A polymer of aspirin is provided by the present invention. Methods of making and using the same are also provided.

Abstract: The assay plate includes a substrate having an substrate surface and at least one raised pad extending from the substrate surface. The raised pad includes a substantially planar sample receiving surface configured for holding a sample thereon for in situ experimentation. The sample receiving surface preferably has at least one sharp edge at the junction between a sidewall coupling the sample receiving surface to the substrate surface. The sample receiving surface is preferably a circle, oval, square, rectangle, triangle, pentagon, hexagon, or octagon shape that is sized to hold a predetermined volume of the sample. A method of using the above described assay plate is also provided. Once a raised pad extending from a substrate is formed, a sample is deposited on the raised pad. Experiments are subsequently performed using the sample on the raised pad.

Abstract: The invention relates to methods and apparatuses for manipulating small amounts of solids. Specific embodiments of the invention are particularly suited for the automated transfer of small amounts of solids. In one embodiment, a uniform powder bed is lightly compressed into plugs of powder and dispensed. In another embodiment, the solid is placed in a liquid carrier to form a slurry, dispensed, and the liquid component is subsequently removed. In yet another embodiment, solids are manipulated using adhesive surfaces.

Abstract: The invention provides novel soluble conazole crystalline forms (e.g. itraconazole, posaconazole and saperconazole) that include salts, co-crystals and related solvates useful as pharmaceuticals. The invention also provides pharmaceutical compositions comprising, and processes for making, these conazole crystalline forms. Methods of using such compositions for the treatment or prevention of systemic and local fungal, yeast, and dermatophyte infections are also provided.

Abstract: Disclosed herein are novel salts of flunarizine with improved properties. Also described herein are novel pharmaceutical compositions comprising such flunarizine salts, methods of making, and related methods of treatment.

Abstract: The present invention relates to a novel crystal of the Active Pharmaceutical Ingredient (API) (S)-(+)-2-(2-chlorophenyl)-2-hydroxy-ethyl carbamate, methods for the preparation of this crystal, pharmaceutical compositions comprising this crystal, and methods of treating a patient with this crystal.

Abstract: The present invention provides methods for the determination of miscibility of a mixture of two or more liquids. Measurements of the local deviation of a pattern characteristic or of the variation in light intensity are employed in such determinations.

Abstract: The present invention relates to computer-controlled high-throughput systems, computer-program products, and methods of use to prepare a large number of component combinations, at varying concentrations and identities, at the same time, and high-throughput methods to test tissue barrier transfer, such as transdermal transfer, of components in each combination. The methods of the present invention allow determination of the effects of inactive components, such as solvents, excipients, enhancers, adhesives and additives, on tissue barrier transfer of active components, such as pharmaceuticals. The invention thus encompasses the use of computer-controlled high-throughput systems, computer-program products, and methods of high-throughput testing of pharmaceutical compositions or formulations in order to determine the overall optimal composition or formulation for improved tissue transport, such as transdermal transport.

Abstract: The present invention relates to a novel crystal of the Active Pharmaceutical Ingredient (API) N-[[(5S)-3 -[4-(2,6-dihydro-2-methylpyrrolo[3,4-c]pyrazol-5(4H)-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide, methods for the preparation of this crystal, pharmaceutical compositions comprising this crystal, and methods of treating a patient with this crystal.

Abstract: The invention provides novel soluble conazole crystalline forms (e.g., cisitraconazole, saperconazole) that include salts, co-crystals and polymorphs useful as pharmaceuticals. The invention also provides pharmaceutical compositions comprising, and processes for making, these conazole crystalline forms. Methods of using such compositions for the treatment or prevention of systemic and local fungal, yeast, and dermatophyte infections are also provided.

Abstract: The present invention provides multifocal lenses containing at least four zones of different refractive power. The zones are positioned such that the wearer is able to use the inferior-most portion of the lens to more clearly, as compared to conventional multifocal lenses, view objects at distances more than 45 cm from the eye.

Abstract: The present invention relates to liquid compositions of nimodipine and administration of said compositions. New stable liquid compositions of nimodipine can be used to treat conditions such as, but not limited to, aneurysms, subarachnoid hemorrhage, vasospastic angina, Prenzmetal's angina, stable angina, acute myocardial infarction, myocardial arrest, arrhythmia, systemic hypertension, pulmonary hypertension, congestive heart failure, and hypertrophic cardiomyopathy.

Abstract: Novel solvates and crystal polymorphs of Ritonavir are disclosed, as well as methods of making them. Specific solvates of the compound include a formamide solvate and a partially desolvated solvate. Also disclosed are methods of making previously known forms of Ritonavir. Methods of using the novel forms of Ritonavir for the treatment of diseases, such as HIV-infection, are disclosed, as are pharmaceutical compositions and unit dosage forms comprising the novel forms of Ritonavir.

Abstract: An acid salt of sertraline, wherein the acid is citric acid, fumaric acid, malic acid, maleic acid, malonic acid, phosphoric acid, succinic acid, sulfuric acid, L-tartaric acid, HBr, acetic acid, benzoic acid, benzenesulfonic acid, ethanesulfonic acid, lactic acid, methanesulfonic acid or toluenesulfonic acid. Similarly, a solvate of sertraline HCl, wherein the solvent is methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, t-butanol, acetic acid, ethyl acetate, or propylene glycol.

Abstract: The present invention relates to high-throughput systems and methods to prepare a large number of component combinations, at varying concentrations and identities, at the same time, and high-throughput methods to test tissue barrier transfer, such as transdermal transfer, of components in each combination. The methods of the present invention allow determination of the effects of inactive components, such as solvents, excipients, enhancers, adhesives and additives, on tissue barrier transfer of active components, such as pharmaceuticals. The invention thus encompasses the high-throughput testing of pharmaceutical compositions or formulations in order to determine the overall optimal composition or formulation for improved tissue transport, such as transdermal transport.

Abstract: A pharmaceutical composition comprising a co-crystal of an API and a co-crystal former; wherein the API has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, pyridine and the co-crystal former has at least one functional group selected from amine, amide, pyridine, imidazole, indole, pyrrolidine, carbonyl, carboxyl, hydroxyl, phenol, sulfone, sulfonyl, mercapto and methyl thio, such that the API and co-crystal former are capable of co-crystallizing from a solution phase under crystallization conditions.

Abstract: The present invention relates to computer-controlled automated high-throughput systems and/or computer-program products to design, prepare, process, and analyze a large number of samples having experimental formulations each containing a compound of interest formulated with differing component combinations and varying concentrations and component identities. The computer-controlled methods of the present invention allow determination of the effects of additional or inactive components, such as excipients, carriers, enhancers, adhesives, additives, and the like, on the compound of interest, such as pharmaceuticals. The invention thus encompasses the computer systems, computer methods, and computer-program products for computer-controlled automated high-throughput testing of pharmaceutical compositions or formulations in order to determine the overall optimal composition or formulation for an intended use or purpose.

Abstract: Computer-controlled automated high-throughput systems can be used to design, prepare, process, screen, and analyze a large number of samples in removable sample vials each containing a compound of interest formulated with differing component combinations and varying concentrations. The computer-controlled methods of the present invention allow for a determination of the effects of additional or inactive components, such as excipients, carriers, enhancers, adhesives, additives, and the like, on the compound of interest, such as a pharmaceutical. The invention thus encompasses the computer systems, computer methods, and computer-program products for computer-controlled automated high-throughput testing of experimental formulations in order to identify experimental formulations that can be further processed. Identified experimental formulations from multiple arrays can be removed and re-arrayed together to form a new array for further processing.

Abstract: The invention relates to pharmaceutical compositions comprising propylene glycol solvates of APIs.

Abstract: The present invention comprises an organic acid salt of gabapentin, wherein the organic acid is tartaric acid, ethanedisulfonic acid, or maleic acid. Methods for modulating the solubility and dose response of gabapentin are discussed. Methods of making organic acid salts of gabapentin are also discussed.